Edwards Group | Bone Oncology
- Botnar
We aim to identify the mechanisms contributing to bone disease caused by cancer and develop new treatments for these conditions.
Metastasis of cancers to bone
Cancer-induced bone disease is a characteristic feature of several types of cancer, including the hematological malignancy multiple myeloma, and other tumors that metastasise to bone such as breast, prostate and lung. In addition to the development of debilitating skeletal complications, the bone marrow provides a unique hospitable microenvironment, and once tumors become established in bone, they are largely unresponsive to treatment.
The overall goal of our research is to elucidate the cellular and molecular mechanisms that contribute to disease pathogenesis, and so identify and validate novel therapeutic approaches. Our focus is on the role of the tumor microenvironment and tumor-host interactions.
Major ThemeS
- Obesity, adipocytes and adipokines in tumour growth and cancer-induced bone disease
- Aging, senescence and dormancy in the tumour-bone microenvironment
- Metabolism in the prostate cancer-bone microenvironment
- Using microfluidics to study the tumour-bone microenvironment
- Circulating tumour cells in prostate cancer bone metastasis
Collaborators
- Prof. Freddie Hamdy
- Prof. James Edwards
- Dr. Srinivasa Rao
- Prof. Ian Mills
- Dr. Ed O'Neill
- Prof Edmond Walsh
- Prof. Colin Goding
- Prof. Jason Davis
- Prof. Alastair Lamb
- Dr. Sarah Gooding
- Prof. Udo Oppermann
- Prof. Adam Cribbs
- Prof. Katja Simon
- Prof. Ester Hammond
- Prof. John Christianson
- Prof. Chris Bunce (University of Birmingham)
- Dr. Karthik Ramasamy
- Prof. Peter Cook
- Dr Michelle Lawson (University of Sheffield)
- Prof. Nikki Horwood (UEA)
Latest publications
Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC).
Journal article
Lowe DM. et al, (2027), Lancet Microbe
Subharmonics are not an infallible safety metric for cavitation dynamics.
Journal article
Wu Q. et al, (2026), Int J Hyperthermia, 43
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Journal article
Coates LC. et al, (2026), RMD Open, 20, e043855 - e043855
Assessing the Importance of Variation in Diagnostic Coding Among the Three Countries in the UK Biobank
Journal article
Clifton L. et al, (2026), Learning Health Systems, 10